White House and Trump announce deals to lower obesity drug prices and expand Medicare coverage
TL;DR Summary
The Trump administration announced deals with Novo Nordisk and Eli Lilly to lower the cost of obesity and Type 2 diabetes drugs for Medicare beneficiaries to $50 copays, aiming to improve access and reduce overall healthcare spending through broader drug pricing reforms.
- White House strikes deals for lower prices on obesity drugs NPR
- Certain obesity drugs will cost as little as $149 and Medicare will start covering them under White House deals CNN
- Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage CNBC
- Trump punches new $35 billion hole in national debt with deal for Medicare to cover your Ozempic Fortune
- The potential impact of lowering the cost of weight loss drugs PBS
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
4 min
vs 4 min read
Condensed
95%
779 → 42 words
Want the full story? Read the original article
Read on NPR